Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study

Yuji Nakamoto, Kaori Togashi, Tomohiro Kaneta, Hiroshi Fukuda, Kotaro Nakajima, Kazuhiro Kitajima, Koji Murakami, Hirofumi Fujii, Mitsuo Satake, Ukihide Tateishi, Kazuo Kubota, Michio Senda

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalJapanese journal of clinical oncology
Volume39
Issue number5
DOIs
Publication statusPublished - 2009 May 15

Keywords

  • 18F-FDG
  • Gastric cancer
  • PET
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Nakamoto, Y., Togashi, K., Kaneta, T., Fukuda, H., Nakajima, K., Kitajima, K., Murakami, K., Fujii, H., Satake, M., Tateishi, U., Kubota, K., & Senda, M. (2009). Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study. Japanese journal of clinical oncology, 39(5), 297-302. https://doi.org/10.1093/jjco/hyp010